Bullseye Biosciences provides a directed‑evolution platform that automates library construction and uses next‑generation sequencing combined with AI analytics to screen billions of protein variants in a single campaign. The service delivers fully characterized, IP‑ready therapeutic candidates and associated data to pharma, biotech, and academic partners for preclinical development or licensing.
Funding
Funding not disclosed
Founders
Product
Problem
Identifying high‑affinity protein therapeutics for complex disease drivers such as cardiometabolic disorders, inflammatory pathways, and oncology targets remains slow and resource‑intensive using conventional discovery methods. Limited library diversity and manual screening workflows hinder the exploration of the vast sequence space needed for novel candidates.
Solution
Bullseye Biosciences operates a directed‑evolution platform that couples automated library construction with next‑generation sequencing (NGS) to interrogate billions of protein variants in a single campaign. Integrated artificial‑intelligence pipelines analyze sequencing readouts to prioritize functional hits and predict developability attributes. The system delivers fully characterized candidate molecules that can be advanced directly into preclinical programs or licensed to partner organizations. By focusing on high‑need therapeutic areas, Bullseye accelerates the transition from sequence to lead while reducing the cost per candidate. The platform is offered through collaborative agreements, enabling pharma and biotech partners to tap into the evolved library without building the underlying infrastructure.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing biologics for cardiometabolic, inflammatory, and oncology indications, as well as academic research groups pursuing protein engineering projects.
Features
- High‑throughput directed‑evolution workflow generating >10⁹ protein variants per run via robotic liquid handling
- Deep sequencing of library populations to obtain quantitative fitness landscapes across multiple selection pressures
- AI‑driven analytics that rank variants by binding affinity, stability, and manufacturability metrics
- Modular assay integration for enzymatic activity, receptor binding, and cell‑based functional screens
- Secure data portal delivering raw NGS data, processed hit lists, and structural models to partner teams
- IP‑ready candidate packages including sequence files, expression vectors, and early‑stage validation data
- Scalable cloud infrastructure supporting parallel campaigns for multiple therapeutic programs